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Ataxia-Pancytopenia Syndrome Is Caused
by Missense Mutations in SAMD9L
Dong-Hui Chen,1 Jennifer E. Below,2,10 Akiko Shimamura,3,4,5,6,11 Sioban B. Keel,4 Mark Matsushita,7
John Wolff,7 Youngmee Sul,7 Emily Bonkowski,1 Maria Castella,6 Toshiyasu Taniguchi,6
Deborah Nickerson,2 Thalia Papayannopoulou,4 Thomas D. Bird,1,7,8,* and Wendy H. Raskind7,8,9,*
Ataxia-pancytopenia (AP) syndrome is characterized by cerebellar ataxia, variable hematologic cytopenias, and predisposition tomarrow
failure and myeloid leukemia, sometimes associated with monosomy 7. Here, in the four-generation family UW-AP, linkage analysis
revealed four regions that provided the maximal LOD scores possible, one of which was in a commonly microdeleted chromosome
7q region. Exome sequencing identified a missense mutation (c.2640C>A, p.His880Gln) in the sterile alpha motif domain containing
9-like gene (SAMD9L) that completely cosegregated with disease. By targeted sequencing of SAMD9L, we subsequently identified a
different missense mutation (c.3587G>C, p.Cys1196Ser) in affected members of the first described family with AP syndrome, Li-AP.
Neither variant is reported in the public databases, both affect highly conserved amino acid residues, and both are predicted to be
damaging. With time in culture, lymphoblastic cell lines (LCLs) from two affected individuals in family UW-AP exhibited copy-neutral
loss of heterozygosity for large portions of the long arm of chromosome 7, resulting in retention of only the wild-type SAMD9L allele.
Newly established LCLs from both individuals demonstrated the same phenomenon. In addition, targeted capture and sequencing of
SAMD9L in uncultured blood DNA from both individuals showed bias toward the wild-type allele. These observations indicate in vivo
hematopoieticmosaicism. The hematopoietic cytopenias that characterize AP syndrome and the selective advantage for clones that have
lost the mutant allele support the postulated role of SAMD9L in the regulation of cell proliferation. Furthermore, we show that AP syn-
drome is distinct from the dyskeratoses congenita telomeropathies, with which it shares some clinical characteristics.Introduction
In 1978, Frederick Pei Li reported a familial cancer suscep-
tibility disease, ataxia-pancytopenia (AP) syndrome, also
called myelocerebellar disorder (MIM: 159550).1 The fa-
ther and all five of his children had onset of ataxia in the
first to third decade of their lives and hematologic cytope-
nias of variable severity. Two of the children died from
bleeding and/or sepsis and two died of acute myeloid leu-
kemia (AML) or myelomonocytic leukemia (AMMoL).2
Somatic loss of chromosome 7 was identified in marrow
from the child with AMMoL and one of the children
with marrow failure.1,2 Stable mild hypogammaglobulin-
emia was documented in the child who developed
AMMoL. Cells from three of the children did not
display increased sensitivity to UV or ionizing radiation
(IR) or mitomycin C (MMC). Ataxia was progressive in
both the father and his surviving affected daughter.
Decreased vibration sense was documented in the
father, but none of the children were reported to have sen-
sory impairments. Computed tomographic (CT) scans of
the father and two of the children showed cerebellar
atrophy, and in both siblings in whom the cerebellum
was examined at autopsy, there wasmarked cerebellar atro-
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 2016 American Society of Human Genetics.cells. In addition, one child had moderate neuronal loss
in the inferior olives and central nuclei. Mildmicrocephaly
was documented in all the affected children. One child
had minor dysmorphic features, and the father and
four children had strabismus. Cognitive ability was normal
in all.
To our knowledge, one other family that appears to fit
the distinct AP syndrome phenotype has been reported.
A mother and her daughter and son manifested sensory
and motor neuropathy in addition to early childhood
onset of cerebellar ataxia.3 The only CT scan described
showed mild cerebellar atrophy in the 5-year-old affected
boy. The mother’s hematologic status appeared to be
normal, but both children had cytopenias. In one child,
monosomy 7 and trisomy 21 were evident in the marrow
karyotype before the development of AML and persisted
afterward.
Ataxia, pancytopenia, and a predisposition to myeloid
malignancies are also observed in patients with dykeratosis
congenita (DC), a genetically heterogeneous group of at
least 13 disorders often associated with the triad of reticu-
lated skin hyperpigmentation, nail dystrophy, and oral
leukoplakia.4–6 Hoyeraal-Hreidarsson syndrome (HHS) is
a severe variant of DC, with the additional manifestations
of cerebellar hypoplasia, microcephaly, and psychomotorf Pediatrics, 4Division of Hematology
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Figure 1. Identification of SAMD9L Muta-
tions in Two Families Affected by Auto-
somal-Dominant AP Syndrome
(A) Family UW-AP, with the c.2640C>Amu-
tation. The segregation of microsatellite-
defined haplotypes on 7q21–7q31 is shown
for all pedigree members from whom a
blood sample was obtained. The location
of SAMD9L is indicated on the STRP sche-
matic, shown per the Marshfield map.
Recombination events in individuals III-6
and IV-2 define a 32 Mb region on the red
haplotype; missing genotypes from con-
necting relatives preclude use of individual
III-1 to further narrow the region. Exome
sequencing was performed on individuals
IV-1 and IV-3.
(B) Family Li-AP, with the c.3587G>C
mutation.
Filled-in quadrants indicate the variable
manifestations in both pedigrees; d. denotes
age at death; c. denotes current age.retardation.4–6 Most patients with DC have very short telo-
meres, a consequence of mutations in genes that encode
components of the telomerase complex or shelterin, impor-
tant in the elongation and protection of the telomeric end,
respectively.6,7 Mutations in five of these genes can cause
HHS—dyskerin (DKC1 [MIM: 300126]8), telomerase reverse
transcriptase (TERT [MIM: 187270]9), regulator of telomere
elongation helicase 1 (RTEL1 [MIM: 608833]10), adrenocor-
tical dysplasia homolog (ACD [MIM: 609377]11), and trf1-
interacting nuclear factor 2 (TINF2 [MIM: 604319]12). It is
well recognized that genetically confirmed DC patients
might not manifest all the characteristic phenotypic find-
ings of the disease. The status of Purkinje cells—preserved
in HHS13,14 and degenerated in AP syndrome—can only
be evaluated on autopsy. Thus, it can be difficult to distin-
guishAP syndrome fromDCon thebasis of clinical findings
alone. For example, the categorization of AP syndrome
in two other reported families15,16 is probably incorrect.
The presence of a TINF2 mutation in one of the families
described as having AP syndrome confirms a diagnosis
of HHS, and indeed this patient had other characteristics
indicative of DC, specifically oral leukoplakia and very
short telomere lengths in multiple leukocyte subsets.12,16
Intellectual disability, dysmorphic features, and cell sensi-
tivity to bleomycin, in addition to cerebellar ataxia and
pancytopenia, argue against AP syndrome in a sporadic
case.15
The overlapping hematologic and neurologic manifesta-
tions of HHS and AP syndrome create some diagnostic
uncertainty, given the variable clinical phenotypes in
both disorders. Here, we describe another multigenera-
tional family with AP syndrome and present evidenceThe American Journal of Human Gthat missense mutations in the sterile
alpha motif domain containing 9-like
gene (SAMD9L [MIM: 611170]) are
the cause of the syndrome in this fam-ily and the one reported by Li et al.1 and document that
HHS and AP syndrome are distinct disorders.
Subjects and Methods
Subjects and Samples
Approval for the recruitment and genetic analysis of these families
was granted by the respective institutional review boards of the
University of Washington, the VA Puget Sound Health Care Sys-
tem, and Harvard University, and all living subjects provided
informed consent. The pedigree of a new family, UW-AP, affected
by familial cerebellar ataxia and pancytopenia is shown in
Figure 1A. Blood samples were collected from 11 individuals across
three generations, and EBV-transformed lymphocyte lines (LCLs)
were established by standard methods. Autopsy material was ob-
tained from one deceased individual. Stored fibroblasts from indi-
viduals I-1, I-2, and II-5 in the Li-AP family2 were cultured and
fibroblasts were grown from a newly obtained skin biopsy from
individual Li-AP II-4 (Figure 1B) by standard methods. Genomic
DNA was extracted from these samples by standard methods.
Exclusion and Linkage Analyses
Exclusion analyses were done by evaluation of short tandem
repeat polymorphic (STRP) markers17,18 flanking genes involved
in multiple ataxias and hematologic disorders (Table S1). A micro-
satellite genome scan using Linkage Mapping Set version 2 was
done as previously described.18 Power and multipoint linkage
analyses for this genome scan were performed with SLINK19,20
and GENEHUNTER version 1.2,21 respectively. The single nucleo-
tide polymorphic (SNP)-based genome-wide linkage analysis was
performed on a subset of SNP genotypes generated from the Illu-
mina HumanOmni1-Quad v.1-0 array, which covers 1,140,419 to-
tal SNPs. A principal component analysis of these results indicated
that reference allele frequencies from the CEU (Utah residentsenetics 98, 1146–1158, June 2, 2016 1147
with ancestry from northern and western Europe) HapMap popu-
lation were appropriate for this family. Summary statistics for
quality control, including sex checks, tests for individual- and
SNP-level missingness, heterozygosity, and identity-by-descent
(IBD) analyses, were performed with PLINK. Mendelian errors
were identified with Pedcheck. Parametric LOD scores were ob-
tained with Allegro.22
Whole-Exome Sequencing
DNAs isolated from peripheral blood of individuals UW-AP IV-1
and IV-3 (Figure 1A) was used for exome sequencing. Target
enrichment and exome sequencing were performed as previously
described.23,24 NimbleGen solution capture arrays, versions 1 and
2, were used for individuals IV-3 and IV-1, respectively, given the
time gap between sequencing of the two samples. Variants were
prioritized on the basis of effect on protein sequence, absence
from the sequence databases dbSNP, Exome Variant Server (EVS),
Exome Aggregation Consortium (ExAC), and 1000 Genomes
Project, evolutionary conservation (Genomic Evolutionary Rate
Profiling [GERP]25 and phastCons26), and predicted effect on pro-
tein structure and function (Sorting Intolerant from Tolerant
[SIFT]27 and Polymorphism Phenotyping v.2 [PolyPhen-2]).28,29
Variant Validation by Sanger Sequencing
Capillary sequencing with customized primers was performed to
confirm the unique coding variants in the linkage regions, to
investigate co-transmission with the AP syndrome phenotype in
all members of the UW-AP family, and to evaluate SAMD9L in
the Li-AP family. Genomic DNAwas PCR amplified with Taq Poly-
merase (QIAGEN) with annealing temperatures shown in Table S1
and sequenced as previously described.23,24
Analysis of Mosaicism and Loss of Heterozygosity
The initially established LCLs from seven affected subjects and
one unaffected at-risk subject in the UW-AP family, as well as
from three of their spouses who married in to the family and
served as control subjects, were thawed for reculture. To confirm
results from these lines, in two affected subjects, LCLs were again
generated from viably frozen mononuclear stocks. DNA was
extracted at 2 week to 1 month intervals for up to 1 year and eval-
uated for presence of the mutation. Allele-specific PCR amplifica-
tion of the SAMD9L c.2640C>A variant was performed with
primers containing either the reference nucleotide or the mutant
nucleotide in the 30 position and a mismatched nucleotide, T, in
the preceding position. A common reverse primer was used for
both mutant and reference alleles (Table S2). PCR products were
visualized and sequenced. The mechanism and extent of loss of
heterozygosity was investigated in one subject with the Illumina
Human Omni1-Quad v.1-0 array and in another subject with the
Illumina Multi-Ethnic Genotyping Array (MEGA), in accordance
with the manufacturer’s instructions (Illumina). Previously
described best practices metrics30 were used to determine the qual-
ity of results. DNA from buffy coat and LCLs at early and later
stages of culture in all available subjects were also analyzed for
read depth of the variant and reference alleles by target capture
and sequencing via a bone marrow failure and myelodysplasia
syndromes (MDS) panel as described.31
Analyses of DNA Repair Response
Tomeasure cellular sensitivity to DNA damaging agents, cells were
seeded in 96-well plates at a density of 15,000 cells/well and1148 The American Journal of Human Genetics 98, 1146–1158, Junetreated with IR with a JL Shepherd Mark I Cesium Irradiator (JL
Shepherd & Associates) at various exposures up to 16 Gy or with
MMC (Sigma, M4287) with increasing doses up to 200 ng/mL.
Cells were incubated for 5 days. Cell survival was measured with
a Cell Proliferation Kit II (XTT) (Roche), according to the manufac-
turer’s instructions. BD0952,32,33 an LCL from an individual with
the FANCI subgroup of Fanconi anemia (FA [MIM: 611360]), was
used as a positive control and LCL PD734 was a normal control.
To evaluate induction of the FA pathway and ataxia-telangiecta-
sia (ATM [MIM: 607585]) and Rad3-related (ATR [MIM: 601215])
signaling, the relevant proteins were quantified via western blot-
ting. Cells were lysed in 0.05 M Tris-HCl (pH 6.8), 2% SDS, and
6% b-mercaptoethanol and boiled for 5 min. SDS-PAGE electro-
phoresis was done with NuPAGE 3% to 8% Tris-acetate gels
(Invitrogen), and proteins were transferred to a nitrocellulose
membrane. Primary antibodies were diluted in blocking buffer
(5% milk in TBS-Tween 20) and incubated overnight. The
following primary antibodies were used: anti-FANCD2 (Abcam,
ab2187), anti-pCHK1 S345 (Cell Signaling, 23415), and anti-
pATM S1981 (Cell Signaling, 4526). Horseradish-peroxidase-
conjugated anti-mouse and anti-rabbit immunoglobulin G (IgG)
(Amersham) were used as secondary antibodies. Images were
acquired via an ImageQuant LAS4000 system (GE Healthcare).Results
Clinical History
The four-generation UW-AP family is of Irish, German, and
Native American ancestry and includes at least nine
affected members, seven men and two women, who have
a disorder characterized by cerebellar ataxia and variable
hematologic cytopenias. The pedigree demonstrates an
autosomal-dominant pattern of inheritance with male-
to-male transmission and variable expressivity and no evi-
dence of incomplete penetrance or genetic anticipation
(Figure 1A). Clinical characteristics of affected familymem-
bers are summarized in Table 1. A branch of the family de-
scended from a sibling in generation II (not shown) is also
reported to contain affected individuals, but records were
not available for review. Onset of neurologic problems re-
ported by patients, most often imbalance as the initial
symptom, ranged from 10 to 62 years, but manifestations
are detectable much earlier by exam. Horizontal and verti-
cal nystagmus and dysmetria are evident in most individ-
uals. Deep tendon reflexes are usually increased, ankle
clonus is easily elicited, and some affected individuals
have extensor plantar responses. Strength and sensation
to touch, vibration, and proprioception are preserved.
Hematologic abnormalities are variable and, in some pa-
tients, intermittent.
Given the phenotypic variability, clinical evaluations of
four affected siblings are described here in more detail. In-
dividual III-3 presented with purpura at 3 months of age,
with pancytopenia characterized by a severe normocytic
anemia (hemoglobin 6.1 g/dL), mild neutropenia (absolute
neutrophil count [ANC] 1,200/mL), andmild thrombocyto-
penia (platelet count 100,000/mL), suggesting trilineage
involvement. He lacked a history of recurrent infections2, 2016
Table 1. Clinical Features of Affected Individuals in the UW-AP Family
Subj
Hematologic Evaluation (Abnormal Measurements/
Total Measurements Available for Review) Neurologic Evaluation
Imaging: Pathology OtherHCT MCV WBC Platelets 3 103
Onset of
Symptoms DTRs Babs
Ankle
Clonus Dysmet Dysarth Nystag Severity
II-3 anemia by
history
NR NR NR 45–50y NE NE NE NE  NE assistance with
walking at ~65 y
ND d. 80 y; lower
GI bleed
II-4 48 (0/1) 91 (0/1) 4.92 (0/1) 148.9–152 (1/2) 62 y [ þ  þ þ H þ V moderate ND d. 85 y
III-3 20–43.8 (2/10) 95–101.4
(3/6)
2.3–4.5
(11/12)
58–201 (3/11) 30 y [ þ/ þ slight mild H þ V mild; gait normal
at 47 y
ND none noted
III-5 19–36 (2/3) NR 1.7–6.0
(4/5)a
5.8–150 (9/10)a unknown NE NE NE NE  NE neurologically
normal
autopsy: severe loss of PC mild coarctation
of aorta; d. 15 y;
retroperitoneal
bleed
III-6 45 (0/1) 95 (0/1) 4.18 (1/1) 132–179 (1/2) 25 y [  þ moderate þ H þ V severe; walker
by 38 y
MRI: marked cerebellar
degeneration; pronounced
in the midline
none noted
III-8 36.5–45.2
(0/20)
94–103.9
(16/19)
3.6–7.8
(9/20)
41–216 (6/23) unknown [ þ left only þ slight  H þ V mild; gait normal
at 38 y
MRI: moderate cerebellar
atrophy, mild white matter
abnormalities
none noted
IV-1 44 (0/1) 87 (0/1) 9.1 (0/1) 326 (0/1) 18 y [  þ þ  H þ V gait normal at 18 y ND none noted
IV-2 29–40 (4/5) 89–108
(1/2)
3.59–5.9
(1/2)
36–444 (1/2) 6 y normal   mild  H þ V gait normal at 16 y ND sagittal suture
craniosynostosis
IV-3 22.2–38.2
(4/12)
81.7–85
(0/9)
2.7–5.9
(8/11)
13–346 (3/11) 10 y [  þ þ  H gait normal at 11 y ND myoclonus, KT
normal when
pancytopenic
Subj, subject; Hct, hematocrit; MCV, mean corpuscular volume; WBC, white cell count; DTRs, deep tendon reflexes; Babs, Babinski sign; Dysmet, dysmetria; Dysarth, dysarthria; Nystag, nystagmus; NR, no records available;
NE, not examined by an author and not included in a reviewed neurologic exam; ND, not done; d., age at death; PC, Purkinje cells; H, horizontal; V, vertical; KT, karyotype.
aEstimated from hospital notes. Terminal hospital admission hematocrit was 19, platelet count was 5,800, and white cell count was 1,700 with no neutrophils.
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Figure 2. Imaging and Pathology of the AP Syndrome
(A) Cerebellar section of individual UW-AP III-5 after death from a
retroperitoneal bleed at age 16 years, stained with anti vimentin
(scale bar, 100 mm). This demonstrates marked loss of Purkinje
cells and milder loss of granule cells.
(B) T-1-weighted sagittal MRI of the brain of individual UW-AP
III-8 at age 38, showing moderate midline cerebellar atrophy
despite mild clinical manifestations.
(C) T-1-weighted sagittal MRI of individual Li-AP II-4 at age 52,
showing marked midline cerebellar and pontine atrophy.
(D) T-2-weighted coronal MRI of individual Li-AP II-4 at age 52,
showing diffuse bilateral abnormal white matter signal.in childhood; however, as an adult, he had chronic gingi-
vitis requiring gum surgery and frequent dental cleanings.
His platelet counts between ages 11 to 47 ranged from
58,000/mL to 177,000/mL, and neutropenia (defined as
ANC < 1,500/mL) was persistent. Bone marrow aspirate at
11 years of age showed hypoplasia with normal matura-
tion but some more immature forms in both the erythroid
andmyeloid series and focal plasmacytosis; marrow biopsy
was not done. Cytogenetic studies were not done. He
developed slowly progressive imbalance at about 30 years
old. At age 47 years, neurologic examination was notable
for nystagmus that was more pronounced with horizontal
than vertical gaze, mild dysarthria, mild finger-to-nose dys-
metria, and hyperreflexia with unsustained ankle clonus.
He had normal gait but difficulty with tandem walking.
The oropharynx was normal without thrush or aphthous
ulcers. There was no angular stomatitis.
At age 1 year, his brother, individual III-5, manifested
ecchymoses and petechiae. Marrow aspirate showed
markedly reduced megakaryocytes. At age 8.5 years, for
the possible diagnosis of thrombopoietin deficiency,
plasma transfusion was administered without evidence of
response. Platelet counts oscillated over the next 20 days,
with a mean of 48,500/mL (range 34,000–64,000/ml). He-
moglobins were 11 - 12 g/dl and white cell counts ranged
from 2,600/ml to 6,000/ml (average 3,500/ml). The marrow
aspirate at that time was hypocellular, with a myeloid
to erythroid ratio of 1:1 and only 1% megakaryocytes.1150 The American Journal of Human Genetics 98, 1146–1158, JuneThere was no frank morphologic or immunophenotypic
dysplasia. Cytogenetic study was not done. He had persis-
tent thrombocytopenia (platelet counts ranging from
50,000 to 150,000/mL) with petechiae and epistaxis. Ataxia
was not mentioned in his medical records or reported by
his family members. At 16 years of age, after a 2 week pro-
drome of pallor, fatigue, and increased petechiae, he was
hospitalized with severe pancytopenia (hematocrit [HCT]
19%, ANC 0, and platelets 5,800/mL). Two bone marrow
aspirates were markedly hypocellular for his age, with
a relative erythroid hyperplasia and absent megakaryo-
cytes. There was no morphologic or immunophenotypic
dysplasia. Marrow biopsy and cytogenetic evaluation
were not done. Despite multiple red cell and platelet trans-
fusions, he developed a retroperitoneal bleed and rectal ne-
crosis, and after subsequent colostomy he died of cardiac
failure. Laboratory studies documented normal protime
and partial thromboplastin time until the day of his death,
when they were increased. Fibrinogen and factors V and
VII levels were normal. The autopsy report stated that there
was ‘‘marked panhypoplasia of the bone marrow with an
increase in plasma cells suggesting a hyperergic form of
suppression.’’ Although there was no history of neurologic
dysfunction, cerebellar and inferior olivary atrophy were
seen, along with severe loss of Purkinje cells (Figure 2A).
In general, white matter was well myelinated, but exten-
sive gliosis of white matter was noted in the hippocampus.
Individual III-6 noted unsteady gait at 25 years that
progressed to severe ataxia, requiring a walker by age 38.
Horizontal and vertical nystagmus, hyperreflexia, ankle
clonus, dysmetria, and moderate dysarthria were all
apparent at age 31; the dysarthria was severe by age 41.
There was no sensory abnormality or cognitive decline.
MRI at age 32 showed marked cerebellar degeneration that
wasmost pronounced in themidline region.Nopontine at-
rophywas identified. Two small foci of high signal intensity
in the frontal whitematter were noted. Only three hemato-
logic laboratory resultswere available for review.Acomplete
blood count at the ageof 43 years, performedwhen the fam-
ily was being evaluated at the University of Washington,
was normal except for a mildly decreased white cell count
of 4.18 3 103/mL with 2.18 3 103/mL neutrophils. Mild to
moderate thrombocytopenia was found at ages 6 and 14
years: 58,000/mL and 132,000/mL, respectively. Clinical
molecular genetic testing was negative for pathologically
expanded repeats in the genes for spinocerebellar ataxia
(SCA) types 1 (ataxin 1 [MIM: 601556]), 2 (ataxin 2 [MIM:
601517]), 3 (ataxin 3 [MIM: 607047]), 6 (calcium channel,
voltage-dependent, p/q type, alpha-1a subunit [MIM:
601011]), and 7 (ataxin 7 [MIM: 607640]).
Because of the family history, their sister, individual
III-8, had a neurologic evaluation at age 25 years.
Her only symptom was ‘‘jumpy legs.’’ Physical exam was
remarkable for horizontal and vertical nystagmus and
ankle clonus. An MRI was reported to be normal. She first
noticed some balance problems with bike riding at age 36.
At that time, her exam also revealed slight finger-to-nose2, 2016
dysmetria and normal gait and tandem walking. Reflexes
were hyperactive with sustained ankle clonus. Two years
later she demonstrated mild difficulty with tandem
walking and a right Babinski reflex was elicited. MRI at
38 years showed moderate cerebellar atrophy and a few
subcortical and periventricular white matter hyperinten-
sities (Figure 2B). Her complete blood counts and red
cell indices were normal until the age of 45 years, when
mild macrocytosis (100–104 fL) without anemia and
intermittent mild neutropenia (white blood cell count
[WBC] 3.63 103/mL and ANC 1.6 3 103/mL) and thrombo-
cytopenia (platelet count 82,000–131,000/ml) became
apparent. Serum folate and B12 levels were normal. At
age 50 years, telomere lengths in hematopoietic cell sub-
sets were measured by Repeat Diagnostics. Unfractionated
lymphocytes, naive T cells (CD45RAþ), memory T cells
(CD45RA), and NK cells (CD57þ) were in the normal
range. Granulocytes and B cells (CD20þ) had low median
telomere lengths at 6.3 kb and 6.2 kb, respectively, as
compared to the medium telomere lengths of 8.0 kb and
7.7 kb, respectively, for her age, but both were above the
sixth percentile. For comparison, dyskeratosis congenita
telomere lengths are typically below the first percentile
in multiple leukocyte subsets.35
The severities of the hematologic and neurologic abnor-
malities are not concordant. Individual III-3 had severe
hematologic manifestations but only very slowly progres-
sive neurologic disability, in contrast to his brother III-6,
who had less severe hematologic manifestations but
much more progressive neurologic manifestations.
Several other clinical features warrant mention. Individ-
ual II-3 suffered from dementia for 10 years and died of
a gastrointestinal hemorrhage at 79. Unfortunately, blood
counts were not available for review. At 6.5 years, individ-
ual IV-3 was given a presumptive diagnosis of aplastic
anemia, supported by results of a bone marrow aspirate.
Cytogenetic analysis showed a normal male karyotype
with a constitutional non-pathogenic polymorphic peri-
centric inversion, 46,XY,inv(9)(p11q13), and no clonal
findings. In addition, two affected individuals had birth
defects—mild coarctation of the aorta in III-5 and sagittal
suture craniosynostosis in IV-2.
Candidate-Gene-Exclusion, Linkage, and Sequence
Analyses in the UW-AP Family
Given the small size of the family, which has a maximum
estimated LOD < 2, candidate genes were initially selected
on the basis of phenotype, and flanking markers were gen-
otyped to evaluate all the SCAs localized at the time and
multiple genes implicated in hematopoiesis (Table S1). By
haplotype analyses, close linkage to all 26 candidate genes
and regions was excluded, except for peptidase, mitochon-
drial processing, beta (PMPCB [MIM: 603131]), which en-
codes a binding partner of frataxin. Sequence analysis of
the coding exons of PMPCB revealed no mutation.
During quality control of the SNP-based linkage analysis,
more than 6,000Mendelian inconsistencies were detected,The Americalmost all of which mapped to the long arm of chromo-
some 7 and nearly all of which involved subject III-3,
whose DNA was from an LCL. Of 3,225 SNPs that showed
Mendelian incompatibility with III-3 and his parents,
3,222 were incompatible with his affected father, II-4.
This excess of Mendelian errors prompted further analysis
of the genotype data of III-3, revealing a region of complete
lack of heterozygosity for almost the entire long arm of
chromosome 7 (Figure 3A). Given that there was no
decrease in signal intensities as would be seen for a dele-
tion (Figure 3B), this most likely reflects uniparental isodis-
omy (UPD) for this portion of the chromosome in the LCL.
This individual was omitted from the linkage analysis
without loss of power because genotypes from his affected
father and two affected children, none of whom exhibited
a similar stretch of homozygosity, allowed recovery of all
missing data. In this analysis, LOD scores greater than
1.5 were obtained on chromosomes 2, 5, 7, 10, and 11,
spanning a cumulative total of 38 megabases (Figure 3E).
Except for chromosome 5, the regions overlapped with
results from a previous microsatellite genome scan that
obtained a multipoint LODmax of 1.63 at chromosome
7q21.11–7q31.2 (data not shown).
Whole-exome sequence data were obtained for individ-
uals UW-AP IV-1 and IV-3. Sequences that failed Genome
Analysis Toolkit (GATK) quality filters other than strand
bias were not further considered. Ranking of the remaining
variants was based on (1) location within the five SNP
linkage regions; (2) coding region sequence effect—
missense, nonsense, coding indels, and splice sites; (3) het-
erozygosity, given the autosomal-dominant inheritance
pattern; and (4) variant frequency—absence from
dbSNP131, the 1000 Genomes Project database, and the
Exome Variant Server (EVS); and (5) was shared by both
exomes or not read (specified as ‘‘N’’ in the exome
sequence data) in one of the exomes. The very small region
on chromosome 2 contained no genes. In the regions of in-
terest, c.2640C>A in SAMD9L (GenBank: NM_152703.3)
on chromosome 7q was the only previously unreported
variant that was shared by both exomes and that cosegre-
gated completely with disease in the UW-AP family,
including individual III-5, whose DNA was later obtained
from a post-mortem kidney paraffin section, and III-3,
when DNA from blood was used (Figure 1C). This variant
predicts substitution of glutamine for histidine at residue
880 (p.His880Gln), affects an evolutionarily conserved res-
idue (GERP25 3.94, phastCons26 0.993, and PhyloP36 1.03),
is predicted to be deleterious by SIFT (0.01)27 and probably
damaging by PolyPhen-2 (0.993),28,29 and is not present in
the ExAC database. We also scanned the exome data for
genes responsible for ATM, DC/HHS,9–12 and autosomal-
dominant ataxias,37,38 but no potentially pathogenic vari-
ants were present.
Hematopoietic Mosaicism in the UW-AP Family
After recognition that the SAMD9L variant allele was ab-
sent in the LCL from individual III-3, LCLs from sixan Journal of Human Genetics 98, 1146–1158, June 2, 2016 1151
Figure 3. Genotyping and Linkage Anal-
ysis in the UW-AP Family
(A) SNPs on chromosome 7 demonstrating
LOH for most of the long arm in a cell
line from III-3. Minor-allele, b, frequency
(MAF) in III-3 (red) is compared to MAF
in an affected relative whose DNA was
analyzed at the same time (black).
(B) Log R ratio of SNP signals show equiva-
lent signal intensities across chromosome
7 for individual III-3 and his relative,
consistent with diploidy.
(C) SNPs on chromosome 7 demonstrating
LOH for most of the long arm in an LCL
from UW-AP individual IV-3. MAF in the
LCL (red) is compared to MAF in his buffy
coat DNA (black), analyzed at the same
time.
(D) Log R ratio of SNP signals in individual
IV-3 shows equivalent signal intensities
across chromosome 7 for both of his sam-
ples, consistent with diploidy.
(E) SNP genome LOD plot of UW-AP. The
LCL sample from individual III-3 was
omitted from the analysis with Allegro
without loss of power because genotypes
from his parents and affected children
were included. There were five regions of
interest with LOD scores greater than 1.5.additional affected individuals (II-4, III-6, III-8, IV-1, IV-2,
and IV-3) were thawed and cultured for up to 1 year and
evaluated periodically for the presence of the mutant
allele. All lines, including those from III-3, were initially
heterozygous, but the lines from III-3 and IV-3 exhibited
loss of heterozygosity (LOH) for the mutant allele after
3 weeks to 6 months. A SNP array performed on IV-3
demonstrated copy-neutral LOH (Figures 3C and 3D), as
was observed in the LCL from III-3 during the linkage anal-
ysis. Figure 3 shows that the borders of LOH in the two in-
dividuals are not identical, as had also been seen by micro-
satellite genotyping. For III-3, the proximal breakpoint was
defined by rs11979094 (7q11.22; chr7:70,111,420), and
the area of homozygosity extended to at least D7S2465
(7q36.3; chr7:156,114,685), at or very close to the termi-
nus of the chromosome. For IV-3, the region of LOH
extended from rs76004043 (7q11.23; chr7:77,154,883) to
rs4255049 (chr7:149,286,695), and the span was broken
up by small stretches of heterozygosity. The UCSC1152 The American Journal of Human Genetics 98, 1146–1158, June 2, 2016Genome Browser (hg19) was used to
define these breakpoints.
The observation of LOH for 7q
in LCLs from two patients raised the
possibility of somatic mosaicism. To
investigate this hypothesis, we re-
generated LCLs from viably frozen
mononuclear stocks from III-3 and
IV-3. In these new LCLs, LOH was
again detectable after 4–16 weeks.
The occurrence of LOH for 7q in inde-
pendently established LCLs stronglysuggests that both patients have somatic mosaicism for
the mutant allele in their hematopoietic systems. We
then used a next-generation sequencing panel for marrow
failure and myelodysplasia syndrome to estimate the pro-
portion of buffy coat and LCL cells that do not carry the
mutant allele of SAMD9L. The sample from affected subject
IV-1 failed. The mutant allele comprised 30% and 42% of
total reads in buffy coat from subjects III-3 and IV-3,
respectively, strongly suggestive of somatic mosaicism for
the mutant allele (Table S3). LCL DNA from IV-3 initially
showed the same proportion of mutant reads as blood,
but after 2 months in culture the variant was substantially
decreased to 5%. The early culture sample from III-3 failed,
but the variant also decreased to 5% by 6months. By allele-
specific amplification, we were also able to monitor the
progressive loss of the mutant allele during culture of
LCLs (Figure 4). Although not quantitative, band inten-
sities after allele-specific amplification were lower for the
mutant allele in buffy coat DNA from III-3 and IV-3, as
Figure 4. Allele-Specific PCR Amplification of the c.2640C>A
Mutation in Blood and LCLs in the UW-AP Family
The mutant allele was amplified with primers containing the
mutant nucleotide, A, in the 30 position and a mismatched nucle-
otide, T, in the preceding position. In unaffected individual III-2
nomutant band was visualized. In blood from all three affected in-
dividuals, IV-1, III-3 and IV-3, a mutant band is seen. In culture of
LCLs from III-3 and IV-3, the mutant band is diminished, as
shown for time points T1 to T3.expected for mosaicism. Furthermore, in contrast to the
equivalent intensities for the wild-type allele throughout
long-term LCL culture, mutant allele bands early in culture
from these two subjects were less intense than those ob-
tained for other affected subjects and were completely ab-
sent late in culture. We observed the same progressive loss
of the mutant allele in newly generated LCLs from these
same subjects, again demonstrating that cells that have
lost the variant allele have a selective growth advantage
in culture.
In two other affected individuals, a downward shift in
the proportion of mutant allele reads from buffy coat to
LCL was observed: 51% to 43% in II-4 and 54% to 44%
in IV-2. These results provide additional support for a selec-
tive advantage in culture of cells without themutant allele,
either lost during culture or reflecting low level hematopoi-
etic mosaicism (Table S3).
Normal Response to DNA Damage and Proficiency of
Repair Pathways
Bone marrow failure and ataxia are hallmarks of FA and
ATM, autosomal-recessive disorders caused by mutations
in DNA repair genes.39–41 To assess DNA repair proficiency
in the AP syndrome, we tested cellular sensitivity to MMC
and IR. No increased sensitivity was observed in LCLs
derived from affected individual UW-AP IV-3 in compari-
son to LCLs from unaffected UW-AP III-2 and PD7, a
wild-type control individual34 (Figures 5A and 5B). In
contrast to the FA LCL, normal induction of FANCD2 ubiq-
uitination, CHK1 phosphorylation at Ser345, and ATM
phosphorylation at Ser1981 by DNA-damaging agents IR
andMMC confirmed efficient activation of the FA pathway
and ATR and ATM signaling in cells from UW-AP IV-3
(Figure 5C).
Analysis of SAMD9L in the Li-AP Family
We had the opportunity to evaluate the one surviving
affected sibling (II-4) from the Li et al. family2
(Figure 1B). She developed mild gait ataxia as an adoles-
cent, was noted to have nystagmus at age 17, and has
had persistent mild anemia. Her occipitofrontal circumfer-The Americence was 52 cm (<third percentile). A bone marrow biopsy
at age 14 showed hypocellularity with normal karyotype. A
marrow sample obtained at age 17 failed to yield mitotic
cells for cytogenetic analyses, both on direct preparation
and after culture for up to 48 hr. At age 54 years, she has
developed moderately severe ataxia and requires a walker
to ambulate. Her mental status is normal and she has
mild horizontal and vertical nystagmus, dysarthria, dys-
metria, bilateral Babinski responses, and mild decreased
appreciation of vibration in her toes. Brain MRI at the
age of 52 years showed severe diffuse cerebellar atrophy
(Figure 2C) as well as diffuse bilateral white matter signals
throughout the cerebrum (Figure 2D). Clinical genetic
testing ruled out abnormalities in an extensive panel of
dominant cerebellar ataxia genes.
Targeted Sanger sequencing of the single large coding
exon of SAMD9L was performed on buffy coat DNA from
individual II-4 and DNA from cultured fibroblasts from
her father (I-1), mother (I-2), and one affected brother
(II-5). A heterozygous missense mutation (c.3587G>C,
p.Cys1196Ser) was identified in all three affected individ-
uals but not in the unaffected mother (Figure 1D). This
mutation affects a conserved residue (GERP 4.88, phast-
Cons 1), is not present in the dbSNP, 1000 Genomes, or
ExAC databases and is predicted to be pathogenic by SIFT
(0.06). The high conservation scores reflect the presence
of cysteine at this position in all primates. The fact that a
glycine residue is present at the homologous position of
all other vertebrate SAMD9L orthologs or paralogs is likely
responsible for the low, predicted benign, PolyPhen score
of 0.009 for the serine substitution. Loss of the variant
allele was not observed in cultured fibroblasts from the
subjects in this family.Discussion
The AP syndrome was first described by Frederick Li,
most noted for his discovery of the disorder known
eponymously as Li-Fraumeni syndrome (MIM: 151623).42
Herein, we provide evidence that missense mutations
in SAMD9L are responsible for the AP syndrome in two
multigenerational families. SAMD9L-related AP is an
autosomal-dominant ataxia with prominent hematopoi-
etic manifestations.37,38 It differs from two other disorders
with combined neurologic and hematologic features.
X-linked sideroblastic anemia and ataxia (XLSA/A [MIM:
301310]) also demonstrates both cerebellar degeneration
and hematologic abnormalities, but the associated mild
anemia is usually asymptomatic.43,44 ATM, an autosomal-
recessive disorder, confers sensitivity to IR and a high risk
for leukemia and lymphoma but not pancytopenia,45
and heterozygotes do not manifest neurologic impair-
ments.46 As was previously reported for the AP-Li family,2
in our study of AP-UW, we observed no increased sensi-
tivity to IR or MMC or impairment of the repair pathways
of FA and ATM.an Journal of Human Genetics 98, 1146–1158, June 2, 2016 1153
Figure 5. Response of UW-AP LCLs to DNA Damaging Agents
Individual UW-AP III-2 is unaffected, UW-AP IV-3 is affected, NC is a normal control, and FA is a patient with Fanconi anemia.
(A) The surviving fraction of treated cells compared to untreated cells after 5 days of exposure to MMC (n ¼ 3, mean5 SEM).
(B) The surviving fraction of treated cells compared to untreated cells 5 days after a dose of IR (n ¼ 3, mean5 SEM).
(C) Quantification byWestern blot of proteins involved in induction of the FA pathway or in ATM or ATR signaling. Cells were harvested
8 hr after treatment with IR (10 Gy) or 24 hr after continuous exposure to MMC (60 ng/mL), as indicated. In contrast to the increased
sensitivity to DNA damaging agents manifested by FA, response of IV-3 was not different from that of III-2 or NC.The two families with most likely pathogenic mutations
in SAMD9L demonstrate marked variation in ages of onset,
rates of progression, and noncoordinate severity of hema-
tologic and neurologic manifestations. In UW-AP, the two
individuals with the most severe cytopenias had relatively
mild ataxia (III-3 and III-5), whereas the one with the most
severe ataxia had mild intermittent cytopenias (III-6).
Persistent moderate neutropenia did not lead to infectious
consequences. Thrombocytopenia was the cause of most
morbidity, with epistaxis, petechiae, and fatal hemorrhage
in at least one affected man (III-5). In contrast to the Li-AP
family and the one other family affected by AP syndrome
(Daghistani-AP),3 no one had dysplastic marrow changes
and no one developed myelodysplasia or leukemia. We
also note that substantial brain pathology might be pre-
sent before neurologic signs are manifest. Individual III-6
had moderate cerebellar atrophy but very mild neurologic
impairment, and III-5 already had substantial Purkinje cell
loss without any observable neurologic problems. The
affected woman in the Li-AP family had slowly progressive
neurologic disease over five decades despite pontine
and cerebellar atrophy and marked diffuse white matter
disease mimicking leukodystrophy. White matter disease
was observed to a mild degree in three affected mem-
bers of the UW-AP family. Although three autosomal-
recessive ataxias have associated white matter disease1154 The American Journal of Human Genetics 98, 1146–1158, June(cerebrotendinous xanthomatosis [MIM: 213700], Nie-
mann-Pick type C [MIM: 257220], and SPAX3 [MIM:
611390]), this is not common in autosomal-dominant
SCAs. Therefore, white matter disease might be a distin-
guishing feature of the autosomal-dominant AP syndrome.
SAMD9L-related AP further expands the category of in-
herited marrow failure syndromes. Patients with classic
presentations of DC, HHS, or AP will fall into distinct cat-
egories, but those with only one hematologic feature can
pose a diagnostic dilemma. Themucocutaneous abnormal-
ities are not present in many cases of DC,47,48 and muta-
tions in DC genes have been found in patients with only
one of the hematologic manifestations.49,50 A subset of
those without mucocutaneous involvement, with or
without obvious cerebellar dysfunction, might have AP,
especially if normal telomere length can be documented.
Therefore, molecular verification will be necessary for an
accurate diagnosis in some of these cases. In addition, it
is possible that AP syndrome might encompass an even
broader clinical spectrum. The proband in the Li-AP family
had microcephaly, strabismus, micrognathia and flattened
malar areas, and clinodactyly; other affected relatives had
mild microcephaly and strabismus.1 The molecular etiol-
ogy in the Daghistani-AP family has not been reported,
so it is not known whether lower extremity weakness
and sensory and motor neuropathy in that family3 are2, 2016
part of the SAMD9L-related AP syndrome. The range of
manifestations of SAMD9L-related AP syndrome and
investigation of genotype effects on the phenotype must
be more fully defined by identification of additional fam-
ilies with germline mutations in this gene.
The role of SAMD9L in human hematopoietic dysplasias
andmalignancies is not known. Human SAMD9L is contig-
uous to a highly conserved paralogous gene, sterile
alpha motif (SAM) domain containing 9 (SAMD9 [MIM:
610456]51). These genes each contain one SAM domain
that has been shown to homo- and hetero-oligomerize,
associate with both SAM-containing and non-SAM-
containing proteins, and bind RNA.52–54 SAMD9L and
SAMD9 are widely expressed in adult and fetal tissues,
including hematopoietic cells and CNS (Human Protein
Atlas), at moderate to high levels. Mutations in SAMD9
are responsible for the autosomal-recessive disorder nor-
mophosphatemic familial tumoral calcinosis (NFTC
[MIM: 610455]),55–57 and there is evidence that SAMD9
is involved in control of cell proliferation and functions
as a tumor suppressor.58,59 The function of SAMD9L is
not well characterized, and to date it had not been causally
related to an inherited human disease. However, evidence
has accumulated that SAMD9L also has a role in cell prolif-
eration, most likely as a tumor suppressor. It is a key anti-
proliferative gene repressed by DNp63a, an oncogene in
squamous cell carcinoma.60 SAMD9L is expressed at lower
levels in breast cancer tissue and hepatocellular carcinomas
than in normal breast or liver tissue from the same pa-
tients.58,61 Somatic mutations in SAMD9L that cluster in
the coding region have been identified in hepatitis-B-
related hepatocellular carcinomas.61,62 Knockdown of
SAMD9L by siRNA or shRNA resulted in enhanced prolifer-
ation and colony formation of multiple hepatocellular
carcinoma cell lines and increased tumorigenicity in
nude mice.61
Relevant to the marrow failure and propensity to
myeloid malignancy observed in the AP-syndrome, studies
in mice heterozygous or homozygous null for Samd9l, the
ortholog of SAMD9L,63 suggest that SAMD9L might func-
tion as a tumor suppressor for myelodysplasia andmyeloid
leukemias.64 At approximately 12 months of age, these
mice develop a myeloid disorder akin to humanMDS char-
acterized by variable cytopenias, marrow hypercellularity,
and morphologic dysplasia, and, rarely, myeloid leukemia.
In comparison to marrow cells from Samd9lþ/þmice, those
from Samd9l/ mice produced more colonies after more
serial transfers. In competitive repopulation transplant
studies into lethally irradiated recipients, Samd9l-deficient
cells preferentially expand compared to Samd9lþ/þ cells,64
further suggesting enhanced reconstitution ability of pro-
genitors in Samd9l-deficient mice.
In contrast to the haploinsufficiency mechanism for
myelodysplasia in Samd9l-deficient mice, in patients with
AP-syndrome with heterozygous mutations of SAMD9L,
marrow hypocellularity without dysplastic features could
reflect a toxic gain of function with suppression of precur-The Americsor cell divisions. It is possible that the neurologic compo-
nent of AP syndrome results from a toxic gain of function
as well, given that neurologic deficits were not reported
and presumably not present in Samd9l-knockout mice.
We can speculate that conversion to marrow hypercellu-
larity and myelodysplasia associated with monosomy 7
in the Li-AP family resulted from loss of the prolifera-
tion-repressive mutant SAMD9L allele, leaving a single
wild-type allele and a haploinsufficient state analogous
to what was seen in mice lacking one copy or both
copies of Samd9l. Consistent with a multistep pathogen-
esis of cancer, progression to myeloid leukemia likely re-
quires additional mutational events. Appropriate samples
from these patients are not available to evaluate this
hypothesis.
Monosomy for all or part of chromosome 7 is a recurrent
karyotypic abnormality in development and progression
of myelodysplasia and myeloid leukemias,65–67 frequently
characterizes treatment-associated hematologic disor-
ders68–70 and inherited marrow failure syndromes,71–75
and is associated with poor prognosis. There is support
for involvement of several non-overlapping segments on
chromosome 7q in this oncogenic process.67 In a study
of juvenile myelomonocytic leukemia with a normal kar-
yotype, 8 of 21 patients had a submicroscopic deletion of
chromosome 7q21.2–7q21.3;51 SAMD9L is one of only
three genes in the shared deletion area. In a targeted anal-
ysis of SAMD9L in sporadic MDS and AML, no SAMD9L
mutations were detected, but 28% of the patients carried
only one copy of the gene.64 A recent comprehensive study
identified one or more genes in band 7q32.3–7q36.1 as
crucial for hematopoietic differentiation in induced pluri-
potential stem cells from patients with MDS.76 This study
noted a proliferative advantage in culture for lines that ac-
quired diploidy of the distal 7q region by segmental UPD.
These observations suggest that SAMD9L plays a role in
sporadic MDS and myeloid leukemia.
Our study of LCLs in two subjects with AP syndrome
provides evidence that cells that are diploid for wild-
type SAMD9L have a selective culture advantage over
those that are heterozygous for mutant SAMD9L. The
most parsimonious explanation for our observation of
mosaic LOH for chromosome 7q in these subjects’ blood
is that hematopoietic precursor clones that lost the
mutant SAMD9L allele and duplicated the wild-type
allele through UPD persist in vivo because of a selective
advantage.
In summary, we show that missense mutations in
SAMD9L are responsible for autosomal-dominant AP syn-
drome, possibly through a gain-of-function proliferation-
suppressive effect. The development of myeloid leukemia
and/or MDS in some patients with AP syndrome and in
Samd9l-knockout mice, together with findings in sporadic
human MDS, strongly suggest that SAMD9L is one of the
crucial genes in the development of sporadic myelodys-
plastic syndromes and myeloid leukemias, including those
characterized by deletions of chromosome 7q.an Journal of Human Genetics 98, 1146–1158, June 2, 2016 1155
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